Log on / register
Feedback | Support | My details
Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
Salido M, Tusquets I, Corominas JM, Suarez M, Espinet B, Corzo C, Bellet M, Fabregat X, Serrano S, Solé F
Breast Cancer Res 2005, 7:R267-73
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.


Methodology    
Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)
Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, Murillo AE, Gaire F, Farrell M, Walk E, Penault-Llorca F, Kurosumi M, Dietel M, Wang L, Loftus M, Pettay J, Tubbs RR, Grogan TM
Diagnostic Pathology 2008, 3:41 (22 October 2008)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles]
2.


Research article    
Real-time PCR complements immunohistochemistry in the determination of HER-2/neu status in breast cancer
Nistor A, Watson PH, Pettigrew N, Tabiti K, Dawson A, Myal Y
BMC Clinical Pathology 2006, 6:2 (18 January 2006)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles]

This article is also cited by a further 1 article in PubMed Central


You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.